Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: COVID-19
Interventions: Remdesivir, RDV Placebo, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more

Conditions: Type 2 Diabetes
Interventions: Joint Home-DM-BAT Intervention, Usual Care; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Colorectal Neoplasms
Interventions: Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 989
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more

Conditions: Pain, Chronic, Opioid Use
Interventions: post-surgical opioid use measured at 1 day and 1 week.; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Uncontrolled Hypertension
Interventions: Baxdrostat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Tempe, Arizona • Montclair, California + 6 more

Conditions: Diabetes Mellitus, Type 2
Interventions: IcoSema, Insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 66
States / cities: Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more

Conditions: Multiple Sclerosis
Interventions: ELND002, Placebo; Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 17
States / cities: Berkeley, California • Fresno, California • Newport Beach, California + 14 more

Conditions: Periodontitis, Diabetes Mellitus Type 2
Interventions: local antibiotic application of topical minocycline, Scaling and Root Planing; Drug · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Catheter-Associated Urinary Tract Infection
Interventions: Bactrim, Placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C); Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 44
States / cities: Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more

Conditions: Tinea Pedis
Interventions: Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo; Drug
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Long Beach, California • Miami, Florida • Miami Lakes, Florida + 3 more

Conditions: Inflammatory Bowel Disease, Intestinal Fistula
Interventions: AST-120; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Anaheim, California • San Carlos, California • Winter Park, Florida + 20 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and simvastatin, Simvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 50
States / cities: Huntsville, Alabama • Chandler, Arizona • Scottsdale, Arizona + 47 more

Conditions: Diabetic Macular Edema
Interventions: Faricimab; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Modesto, California • Sacramento, California • Oak Forest, Illinois + 7 more

Conditions: Breast Cancer - Female
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Obesity
Interventions: Cannabis, Placebo; Drug
Lead sponsor: Joshua A. Lile, Ph.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Musculoskeletal Pain
Interventions: CBD, Control; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo, Topical Corticosteroid; Biological · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 43
States / cities: Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more

Conditions: Fatigue
Interventions: Unbundling of cords, Bundling of cords; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyperkalemia
Interventions: Placebo, Sodium Zirconium Cyclosilicate(ZS), Insulin, Glucose; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Montgomery, Alabama • Phoenix, Arizona • Detroit, Michigan + 7 more

Conditions: Healthy Participants
Interventions: STAR-0310, Placebo; Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Working Memory
Interventions: Transcranial alternating current stimulation (tACS); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: ixmyelocel-T, Placebo; Biological · Other
Lead sponsor: Vericel Corporation; Industry
Eligibility: 30 Years to 86 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 27 more

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes

S0820, Adenoma and Second Primary Prevention Trial

Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

Cannabis for Obesity Trial

Topical CBD for Musculoskeletal Pain

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

Bundling and Unbundling the Laparoscopic Electrosurgery Cord With the Camera Cord

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

A Study of STAR-0310 in Healthy Adult Participants

Traveling-wave Transcranial Electric Stimulation

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)